|
Belarus has sought collaboration with the Indian pharma companies for Joint Ventures in areas of anti-cancer and immunosuppressant drugs towards business expansion. This is a major development for the Indian pharma industry as Belarus is the main gateway to the Central European market.
“Discussions are further on to explore business opportunities in the areas of biosimilars, complex generics and other advanced therapies,” informed Lakshmi Prasanna, director, regulatory affairs, Pharmexcil.
India is the fifth among the top 10 formulations importing partners of Belarus with imports worth US$ 44.98 million in 2019, US$ 46.94 million in 2020 and US$ 51.50 million in 2021 contributed from India. Locally produced products account for about 80% of the market share. Belarus had a market size of US$ 1.42 billion in 2022 with patented medicine market share at 10.11% worth US$ 143.5 million, generics with a share of 53.2% worth US$ 754.6 million and OTC market share at 36.7%.
The Republic of Belarus is located in the center of Europe. The shortest transport links connecting the CIS countries with the states of Western Europe run through its territory. Belarus has a common border with Poland, Lithuania, Latvia, Russia and Ukraine. The central position of Belarus in Europe is of great importance for the development of trade.
Belarus is largely dominated by the state owned Belarus Pharmaceutical Holdings Companies led by “Belpharmprom.”
The Indian pharma companies have a good presence in Belarus. BDR Pharmaceuticals International Pvt Ltd has invested US$ 13 million to acquire a controlling stake in a Belarus Government owned pharma unit.
Belarusian Belmedpreparaty, Novalok - India has formed Lok -Beta Pharma India Pvt Ltd Joint Venture.
Cipla launched Yusuf Hamied Pharma R&D Center in August 2018 at the premises of the Academfarm of the National Academy of Science (NAS) of the Republic of Belarus in Minsk. One million USD was the investment made by Cipla for the same.
Natco Pharma participated in the creation of the state of the art biotechnological and generic medicines production facility, NatiVita with an investment of US$ 15 million investments from Natco Pharma (India), Biocad (Russia), Belarusian medicine distributor VitVar as well as Lithuanian investment company ZIA Valda.
The Belarusian-Indian Pharmaceutical Forum which was recently organised by Pharmexcil in association with the Belarus Pharmaceutical Holdings Company “Belpharmprom” during XXVIII International Medical Forum “Healthcare of Belarus” concluded successfully between May 23 and May 26, 2023 at Minsk, Belarus.
|